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Elevated circulating levels of interleukin-6 in patients with
chronic renal failure
ANDRE HERBELIN, PABLO URErA, ANH THU NGUYEN, JOHANNA ZINGRAFF,
and BEATRICE DESCAMPS-LATSCHA
INSERM U 25 and CNRS UA 122, INSERM U 90, Hôpital Necker, Paris, France
Elevated circulating levels of interleukin-6 in patients with chronic
renal failure. In a previous study, we demonstrated the presence of
circulating interleukin-l (IL-I) in long-term dialyzed patients and that of
tumor necrosis factor alpha (TNFa) in both long-term and not yet
dialyzed uremic patients. In the present study, we attempted to
determine the respective influence of hemodialysis (HD) and uremia on
the plasma level of interleukin-6 (IL-6), which shares several biological
properties with IL-I and TNFa, including the induction of the acute
phase response of the inflammatory process. Forty-eight patients with
end-stage renal failure, including 32 long-term HD patients and 16
chronic uremic patients undergoing their first dialysis session, were
tested for plasma IL-6 using both biological and immunoreactive
assays. Plasma IL-6 activity was significantly increased in patients with
chronic renal failure (P < 0.001) compared to its level in normal
individuals. No difference was observed, however, between long-term
and not yet dialyzed patients. In the patients with the most pronounced
IL-6 activity, immunoreactive IL-6 levels between 60 and 150 pg/mI
were detected. A monoclonal antibody (mAb) against human IL-6
inhibited the activity of plasma in the IL-6 bioassay, and a close
correlation existed between the biological activity of IL-6 and its
immunoreactive level. No change in plasma IL-6 was detected during
the course of the first dialysis as well as subsequent sessions. Likewise,
no influence of the nature (cellulosic or synthetic polyacrilonitrile) of
the dialysis membrane equipping the dialyzer was observed. However,
compared to predialysis levels, a significant increase in plasma IL-6 was
measured four hours following the end of the dialysis session in
long-term HD patients, thus contrasting with the relative decrease
measured in first-dialyzed patients. Lastly, in long-term HD patients,
there was a significant correlation between maximum plasma IL-6
(measured 4 hr postdialysis) and maximum plasma IL-l (measured at
the end of the dialysis session). From these results, we conclude that
uremia per se is the principal origin of increased plasma IL-6 and that
factors related to repeated dialysis procedure including IL-l may
contribute in maintaining increased plasma levels of IL-6.
Growing interest has focused in recent years on the possible
role of cytokines in the acute phase response of the inflamma-
tory process. Among these, interleukin-l (IL-I) [1] and tumor
necrosis factor alpha (TNFa) [21, two cytokines mainly derived
from activated monocytes, are thought to contribute to acute
and chronic inflammatory changes associated with hemodialy-
sis (HD) treatment [3, 4]. Both circulating IL-i and TNFa have
been shown to be significantly increased in end-stage renal
patients maintained on long-term HD [5—71. In addition, ele-
vated plasma TNFs levels were also detected in not yet
dialyzed patients with end-stage renal failure, suggesting that
uremia related factors could also induce cytokine production
[8].
Recently, the eDNA of another monocyte product, interleu-
kin-6 (IL-6), was cloned. It can also be detected in the circulation
and is mainly involved in the acute phase of the inflammatory
response. IL-6 was originally described as interferon-beta-2, 26
kDa protein, B cell stimulating factor-2 and hybridoma growth
factor [9—12]. In human peripheral blood, monocytes are the main
source of IL-6 [13]. Although IL-i, TNFa and IL-6 are biochem-
ically and immunologically distinct, they share many in vivo
activities including induction of fever, liver acute-phase protein
synthesis, hemodynamic shock and a catabolic effect on bone and
connective tissues [1, 2, 12, 14—161. Further studies indicated the
numerous interactions existing among these cytokines. For exam-
ple, IL-6, IL-I and TNFa increase alpha-I acid glycoprotein and
decrease albumin gene expression in a synergistic manner [17];
IL-6 and TNFs potentiate T cell proliferation induced by IL-I [18,
19]; both IL- 1 and IL-6 enhance synthesis of immunoglobulins by
B cells, but promote B cell growth only when used together [10,
20]. Moreover, the production of these cytokines is closely
related. IL-I and TNFw can induce each others' cytokines as well
as IL-6 both in vivo and in vitro [21—24], while IL-6 may provide
a negative feedback in this self-augmenting network of cytokines
[22].
To our knowledge, IL-6 has not yet been investigated in
patients with chronic renal failure, whereas studies have been
reported in acute clinical situations [25, 26]. Our previous
observations indicating an apparent dissociation between IL-I
and TNFa plasma levels in not yet dialyzed patients prompted
us: 1) to investigate whether circulating IL-6 was present in not
yet and long-term dialyzed patients and may possibly be corre-
lated with the levels of IL-i and TNFa that we previously
determined in the plasma of these patients, and, 2) to attempt to
determine the influence of the HD procedure in both first and
long-term dialyzed patients on circulating IL-6 levels.
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Methods
Study population
Forty-eight patients with end-stage renal failure participated
in the study upon informed consent. Thirty-two of them were
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Table 1. Patient characteristics
Long-term
Not yet dialyzed dialyzed
uremic patients patients
Total: 16 32
Age
years, mean SEM 50.8 2.6 46.5 4.8
Sex
male/female 8/8 19/13
Dialysis duration
months, mean SEM 0 63.0 7.0
Kidney disease
Chronic glomerulonephritis 6 6
Interstitial chronic 4 7
nephropathy
Polycystic kidney disease 1 3
Congenital uropathy or 1 2
urinary tract
malformations
Nephroangiosclerosis 2 6
Alport's syndrome 0 1
Diabetic nephropathy 0 1
Amyloidosis 0 2
Unclassified 2 4
stabilized on renal replacement therapy for more than six
months prior to the study and were undergoing from four to five
hours of maintenance HD thrice weekly. The other 16 patients
were not yet dialyzed and were tested just before and during
their first dialysis session. Patient characteristics, including age,
sex and renal etiology are listed in Table 1. None of the patients
had clinical evidence of acute infection or underlying tumoral or
autoimmune disease. All patients were dialyzed with standard
capillary artificial kidneys equipped with cellulosic membranes
that were never reused. The dialysate routinely used contained
bicarbonate; only in four young patients was acetate dialysate
used. Thirty-three healthy subjects recruited among volunteer
blood donors served as controls.
To investigate the influence of the nature of the dialysis
membrane equipping the dialyzer, plasma samples from two
groups of long-term chronic HD patients (10 patients treated
with cellulosic and 10 with synthetic polyacrilonitrile (PAN
AN-69, Hospal) membranes) were also tested; plasma from 10
normal subjects served as controls (see Results, Table 3). These
patients had previously participated upon informed consent in a
randomized prospective study performed for defining the rela-
tionships between complement activation and phagocyte me-
tabolism activation (see Note added in proof) and were carefully
matched for sex, age, weight, initial nephropathy and HD
duration.
Plasma preparation
Patient blood samples of 5 to 10 ml were collected in
heparinized tubes (Liquemine Roche, Paris, France, 10 U/mI of
blood) from the arterial site of the arteriovenous fistula at the
start, the end and four hours after the end of dialysis sessions.
In normal subjects, blood samples were obtained by cubital
venous puncture. Blood samples were centrifuged (600 X g, 10
mm). The plasma was separated into small aliquots and frozen
at —70°C. All the assays were carried out on samples thawed
only once.
Interleukin-6 activity assay
Interleukin-6 was measured by its capacity to induce the
proliferation of the IL-6-sensitive B9 cell line (provided by Dr.
L. Aarden, Central Laboratory of the Netherland Red Cross
Transfusion Service, Amsterdam, The Netherlands) 1131. The
B9 cell line was maintained in Iscove medium (Biochrom KG,
Berlin, Germany) supplemented with 2 mM L-glutamine, peni-
cillin (100 lU/mI), streptomycin (100 g/ml), 5% heat-inacti-
vated fetal calf serum (FCS, Flow Laboratories Limited, Irvine,
UK) (referred to hereafter as culture medium) and a P388D1
conditioned medium as a source of IL-6 (provided by Dr. M.
Dy, INSERM U 25 and CNRS UA 122, Hôpital Necker, Paris,
France). After three washes to eliminate traces of remaining
IL-6, B9 cells were resuspended in culture medium and further
incubated at a density of 5000 cells (50 Ml) per well of 96-well
flat-bottomed culture plates (Falcon 3072, Becton-Dickinson
and Co, New Jersey, USA) with 50 M1 of serial dilutions of
duplicate plasma samples for 72 hours. Cellular proliferation
was measured by the MTT (dimethyl-thiazol-2-yl diphenyltet-
razolium bromide, Sigma Chemical Co, St Louis, Missouri,
USA) colorimetric assay [27] at 570 nm using a microplate
reader (MR 5000, Dynatech, Alexandria, Virginia, USA) with a
reference filter at 630 nm. Recombinant human interleukin-6 (r
hu IL-6, Janssen Biochemica, Beerse, Belgium), titrated along
with the unknown plasma samples, was diluted in heat-inacti-
vated human AB plasma and tested as internal positive control.
One IL-6 unit was defined as the concentration that leads to
half-maximal B9 cell proliferation. r hu IL-6 induced half-
maximal proliferation of B9 cells between 0.5 and 2 pg/mI in
several assays. Before testing, plasma samples were heated at
56°C for 30 minutes. Under these conditions, the detection limit
of IL-6 in plasma was about 4 U/mI, and it was verified that
addition of up to 25% heat-inactivated plasma had no effect on
the IL-6-sensitive assay. IL-l and TNFa were inactive in this
assay. The specificity of the B9 response to IL-6 was tested
with a murine anti-human IL-6 monoclonal antibody (mAb)
provided by Ire-Medgenix (lGl2 anti-IL-6 mAb, Fleurus, Bel-
gium). In the neutralization experiments, plasma samples were
incubated for four hours at 37°C with a concentration of 2 g/ml
of the I G 12 anti-IL-6 mAb (vol/vol) or murine-unrelated immu-
noglobulin type-matched antibody (as control) and then tested
in the IL-6-sensitive assay. In these conditions, we found that
this antibody, when used at 2 g/ml (vol/vol), abrogated the
biological activity mediated by more than 100 pglml of r hu
IL-6.
Immunoassay for IL-6
A commercial, enzyme-linked immunosorbent assay (ELISA,
IL-6 Quantikine, R&D Systems, mc, Minneapolis, Minnesota,
USA) was used according to the manufacturer's suggestions for
measuring IL-6 levels in plasma samples. All plasma samples
were tested in duplicate. The lowest concentration of r hu IL-6
detectable in plasma from the zero level was 60 pg/mI. Plasma
samples below the detection limit were assumed to have a value
of 30 pg/mI.
In?munoassays for IL-I and TNFa
A commercial, enzyme-linked immunosorbent assay
(ELISA, Cistron Biotechnology) was used according to the
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Fig. 1. Plasma IL-6 activity in 32 long-term and 16 first-dialyzed
chronic uremic patients before the dialysis session and 23 control
subjects. Each point represents the mean of plasma IL-6 activity
measured in duplicate on two separate occasions for each patient.
Plasma IL-6 activity is significantly increased in both first and long-term
dialyzed patients, compared to normal subjects (P < 0.001).
manufacturer's suggestions for measuring IL-i levels in plasma
samples. The antiserum in this assay was shown to be specific
for IL-i and the lowest concentration of IL-i detectable from
the zero level was 15 to 20 pg/mI. For measuring TNFa levels in
plasma samples, a commercial immunoradiometric assay
(IRMA-TNF alpha) purchased from Ire-Medgenix (Fleurus,
Belgium) was assessed using specific rabbit polyclonal antisera
and iodinated TNFa molecules. This IRMA-immunoassay
showed a detection limit of 15 pg/mI for TNFa. Plasma samples
below the detection level of 15 pg/mI of IL-i or TNFs were
assumed to have a value of 7.5 pg/mI.
Presentation of results and statistical analysis
In long-term dialyzed patients, unless otherwise specified,
each post-HD cytokine plasma level was corrected according to
hemoconcentration measurement using the method described
by Bergstrom and Wehle [28]. Such correction was not made in
patients undergoing their first dialysis since no ultrafiltration
was performed. All samples from one patient were analyzed in
duplicate in the same batch on two separate occasions and the
mean result was used. Results are expressed as mean SEM.
Significance is assessed using Student's t-test for paired values
(pre- to postdialysis U/mI) and unpaired values (U/mI of normal
controls vs. chronic uremic patients predialysis). Differences
were considered to be significant when P was less than 0.05.
Results
Plasma JL-6 levels in chronic uremic patients
Figure 1 illustrates the results obtained in the determination
of plasma IL-6 activity by the B9 IL-6-sensitive assay in 16
patients undergoing their first dialysis session, 32 patients
stabilized on renal replacement therapy for more than six
months and 23 healthy control subjects. All patients were tested
Table 2. Biological and immunoreactive IL-6 activities in plasma
from 10 chronic uremic patients
Patient 1 2 3 4 5 6 7 8 9 10
IL-6 biological activity 120 100 75 70 60 55 55 50 40 25
(UIml)a
Antj-IL-6 mAb-induced 78 72 77 73 71 82 70 71 85 54
inhibition (%)b
IL-6 immunoreactjve 150 120 120 120 30 60 30 60 30 30
level (pglml)c
a Measured by the B9 assayb % inhibition =
—
U/mI of plasma sample in the presence of anti-IL-6 antibody
< 100U/mI of plasma sample in the presence of control antibody
"Measured by ELISA
at the start of the dialysis session and as shown on Table 1 no
major differences were observed with respect to age, sex, and
the distribution of initial nephropathy between the two groups.
Compared to its level in healthy control subjects (20.6 1.8
U/mI), plasma IL-6 activity was significantly higher in both
long-term (45.2 3.9 U/mI, P < 0.001) and first-dialyzed (50.7
6.7 U/mI, P < 0.001) patients. A significant increase in
plasma IL-6 (40 U/ml corresponding to mean level + 2 sr of
control subjects) was found in 10 of 16 not yet dialyzed patients
and 19 of 32 long-term dialyzed patients against only I of 23
control subjects (P < 0.001 according to test). No significant
difference was observed between the two groups of patients.
To verify that plasma-induced B9 cell proliferation was due to
IL-6, plasma samples with IL-6 activity were tested in the
presence of an anti-IL-6 mAb. As shown in Table 2, evidence
that the activity detected in plasma samples is attributable to
IL-6 was obtained for all plasma samples exhibiting pronounced
IL-6 activity. In these plasma, IL-6 biological activity was
significantly neutralized (70 to 85% of inhibition) by the anti-
IL-6 mAb and was further evidenced by using an ELISA
specific for human IL-6. Although the average sensitivity of this
immunoassay for measuring IL-6 in plasma samples is about 50
to 100 less than that of the B9 bioassay, we detected significant
IL-6 immunoreactive levels in all but one plasma sample
containing at least 60 U/mI of IL-6. In addition, a significant
correlation (r = 0.81, P < 0.001) was found between the results
of the ELISA and the bioassay. Lastly, no significant IL-6
immunoreactivity could be detected in plasma samples from
control subjects (data not shown).
Effect of the dialysis session
Figure 2 compares plasma IL-6 activity at the start and the
end of a single dialysis session in both first- and long-term
dialyzed patients. No major modification of plasma IL-6 levels
could be evidenced in either group of patients when studied at
the start and the end of the dialysis sessiOn. Long-term HD
patients showed no intradialytic change in plasma IL-6 activity
before (44.8 5.8 U/mI) compared to after (43.5 5.0 U/ml and
50.5 6.2 U/ml; corrected and unèorrected for hemoconcen-
tration, respectively) a dialysis session, while first-dialyzed
patients showed a nonsignificant decrease from 50.7 6.7 U/mI
to 45.8 7.3 U/ml. Additionally, IL-6 levels remained un-
changed regardless of the time of sampling during the course of
the dialysis session, that is, 15, 30 and 90 mm after the start of
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Fig. 2. Plasma !L-6 activity in 20 long-term and 16 first-dialyzed
chronic uremic patients at the start (TO) and the end (Ti) of a single
dialysis session. Each point represents the mean of plasma IL-6 activity
measured in duplicate on two separate occasions for each patient.
Compared to its predialytis level, plasma IL-6 activity did not signifi-
cantly differ at the end of the dialysis session in both groups of patients.
dialysis procedure (data not shown) and no influence of the
(cellulosic or synthetic) nature of the membrane equipping the
dialyzer could be detected in long-term HD patients (Table 3).
Finally, the possibility of changes in IL-6 was also assayed
four hours following the end of the dialysis session in seven
first-dialyzed patients and in 13 long-term HD patients (Fig. 3).
In long-term HD patients, there was a highly significant in-
crease of IL-6 plasma levels measured four hours following the
end of the dialysis session (65.7 9.4 U/ml; uncorrected for
hemoconcentration) compared to both pre- (41.9 5.4 U/mI, P
<0.001) and post- (38.6 5.0 U/mI; uncorrected for hemocon-
centration; P < 0.002) dialysis levels. Plasma IL-6 activity
measured four hours following the dialysis session was signifi-
cantly increased over predialysis values in all but three patients
tested. In these latter no significant difference as to age,
nephropathy, or dialysis condition could be evidenced as com-
pared to the other patients who did show a delayed postdialysis
increase in IL-6 plasma levels. With regard to dialysis duration,
two of the three patients had very long-standing time on dialysis
(17 and 14 years, respectively) but the other patient had been
dialyzed for less than two years. Lastly, with regard to associ-
ated treatment, none had nonsteroid antiinflammatory drugs but
all three patients were given vitamin Bl and B6 supplementa-
tion and various analgesic medications (paracetamol). In con-
trast, a relative decrease in plasma IL-6 levels was observed in
first-dialyzed patients at the same time of sampling (36.5 4.6
U/ml) compared to both pre- (47.7 5.1 U/mI, P < 0.05) and
post- (46.8 4.5 U/mi, P < 0.001) dialysis levels.
Comparison of plasma levels of IL-6, IL-i and TNFs
In a previous study 181, we demonstrated the presence of IL- 1
and TNFa in the plasma from patients stabilized on renal
replacement therapy. We therefore decided to determine the
relationships between IL-6 and IL-i or TNFa in these patients.
Figure 4 shows the regression analysis between these cytokines
in plasma samples from eight long-term dialyzed patients. For
each patient tested, cytokine levels were measured by immu-
noreactive assays in the same plasma sample collected at the
start, the end and four hours following the end of the dialysis
session; Before the start of the dialysis session, significant
correlation was found between IL-6 and IL-i (r = 0.83, P <
0.01); correlation between predialysis IL-6 and TNFa levels
was less but still significant (r = 0.79, P < 0.02). Interestingly,
the best correlation (r = 0.92, P < 0.001) was found between
maximum IL-6 (observed 4 hr postdialysis) and maximum IL-i
(at the end of the dialysis session). At the same time of
measurement, correlation between IL-6 and TNFa plasma
levels was poorly significant (r = 0.63, P = 0.05). Among not
yet dialyzed patients, since only 2 of the 16 patients tested
exhibited significant plasma IL-i levels (that is, 20 pg/ml), no
evidence for correlation between IL-6 and IL-i could be
demonstrated.
Discussion
The present study demonstrates that IL-6 is significantly
increased in the plasma of long-term HD patients as compared
to normal subjects, regardless of the nature of the membrane
equipping the dialyzer. However, comparable plasma IL-6
levels were also observed in not yet dialyzed uremic patients.
During the course of the first as well as a routine dialysis
session, plasma IL-6 levels remained unchanged. However, as
compared to predialysis values, a significant increase in plasma
IL-6 was found four hours following the end of the dialysis
session in long-term HD patients. Altogether, these results
would indicate that factors related to uremia are the principal
origin of increased IL-6 in the plasma and that the HD proce-
dure leads to a further induction of IL-6. We established that
IL-6 is responsible for the observed B9-induced proliferation
since it was neutralized by an anti-IL-6 mAb in all plasma
exhibiting significant IL-6 biological activity. In addition, sig-
nificant immunoreactive IL-6 levels (comprised between 60 and
150 pg/mI) were detected in all but one plasma sample having
the most pronounced IL-6 biological activity (60 U/ml).
The observation that not yet dialyzed patients with chronic
renal failure show increased IL-6 plasma levels could be related
to our previously reported study showing the presence of
circulating TNFa but not IL-i in these patients [8]. Although it
is well established in vitro that IL-6 production by peripheral
blood monocytes is associated with the production of IL-I and
TNFa [22], the possibility that IL-6 and TNFa, but not IL-I,
are generated in these patients could not be excluded. Alterna-
tively, it could be due to the fact that IL-i can remain
cell-associated after its induction [22] whereas IL-6 and TNFa
are immediately secreted [22, 29].
It can thus be proposed that the increased plasma levels of
IL-6 and TNFs in not yet dialyzed patients are associated to an
activation state of monocytes. Previous findings of Beaurain et
at [30] demonstrated the presence of activated T cells in these
patients as reflected by increased expression of their membrane
interleukin-2 receptors (IL-2 R). Since it has recently been
reported that IL-6 is capable of inducing IL-2 R expression by
T cells [31], activated monocytes producing IL-6 could be
involved in the mechanisms of T cell activation in these
To Tf To
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Table 3. Influence of the nature of the dialysis membrane on plasma IL-6 levels in long-term dialyzed patients
Cellulosic membranes
Long-term HD patients treated with:
Controls T0 Tf T0 Tf
IL-6 activity 20.6 l.20' 38.6 5.5 43.9 4.7 45.7 6.8 51.3 6.15
U/mi (lO)b (10) (10) (10) (10)
Polyacrilonitrile membranes
IL-h activity was determined in plasma obtained at the start (T0) and the end (Tv). of a dialysis session in patients treated with cellulosic or
synthetic polyacrilonitrile (PAN-AN 69) membranes. Compared to normal subjects, predialysis IL-6 levels are significantly elevated in patients
treated with both cellulosic (P = 0.005) and PAN-AN 69 (P — 0.002) membrane equipped dialyzers. No significant change over predialytic values
could be detected in either groups of patients.
a IL-6 activity, mean ÷SEM.b Number of cases in each group tested
A B
A
Predialysis IL-i, pg/mi
/g:
Postdialysis IL-i, pg/mi
.'
n
°-
B
140
120
cnIlOO
60 .' r = 0.79
40 P — 0.02
-
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2.
'
w
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Fig. 3. Evolution of plasma IL-6 activity between the start, the end and
4 hours following the end of a single dialysis session in 7 first- and 13
long-term dialyzed patients. Plasma IL-6 activity was measured in
duplicate on two separate occasions for each patient. In long-term HD
patients, plasma IL-6 activity significantly increased 4 hours after the
end of the dialysis session compared to both pre- (P < 0.001) and post-
(P < 0.002) dialysis levels. This increase still remains highly significant
(P < 0.02) when excluding the two patients who had the highest levels
of IL-6 at Tf + 4 hr' In first-dialyzed patients, plasma IL-6 activity
significantly decreased 4 hours after the end of the dialysis session
compared to both pre- (P < 0.05) and post- (P < 0.001) dialysis levels.
Postdialysis values were not corrected for contraction of extracellular
volume for allowing comparison between T1 and Tf + 4 hr (fluid shifts
during this 4 hour period are difficult to evaluate).
patients. Alternatively, it is also possible that activated T cells
themselves [32] contribute to the increased plasma levels of
IL-6 in not yet dialyzed patients. Interestingly, production in
vitro of IL-6 by T cells depends on the presence of monocytes
[32].
Among the factors capable of inducing the production of IL-6
by monocytes in not yet dialyzed patients, particular attention
should be given to endotoxins. Recent reports have shown that
the administration of minute amounts of endotoxins to normal
volunteers induces consistent levels of circulating IL-6 and
TNFa but not IL-I [33, 34], that is, mimicking the pattern of
0 40 80 120 0 40 80 120
Predialysis TNF, pg/mi Postdialysis TNF, pg/mi
Fig. 4. Relationships between plasma cytokine levels measured by
immunoassay in eight long-term dialyzed patients. A. Relationship
between IL-6 and iL-I. B. Relationship between IL-6 and TNFa.
Before the dialysis session, mean plasma levels were: IL-l (39.7 8.2
pg/mI); IL-6 (48.2 7.0 pg/mI); TNFa (53.4 15.8 pg/mI). At the end
of the dialysis session, mean plasma levels were: IL-I (65.6 13.6
pg/mi); TNFa (48.7 ÷ 13.4 pg/mI). Four hours following the end of the
dialysis session, mean IL-6 plasma level was: (78.6 13.4 pg/mI).
Postdialysis values were not corrected for hemoconcentration (see
legend, Fig. 3).
these respective cytokines in the plasma of uremic not yet
dialyzed patients. Interestingly, the presence of significant
amounts of circulating endotoxins has also been reported in not
yet dialyzed patients [35].
Although activated monocytes and T cells could both be
responsible for increased circulating TNFx and IL-6 levels in
these patients, one must also consider the possibility that
chronic renal failure itself could participate in dysregulation of
the production and elimination of these cytokines. Indeed, the
reduced glomerular filtration rate could lead to their defective
clearance from the plasma. In support of this hypothesis are the
observations that cytokines can be detected in the urine of
normal subjects [36—38]. The alterations in tubular cells could
likewise be incriminated since these cells contain high concen-
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trations of uromodulin (Tamm-Horsfall protein) which plays a
prominent role in the regulation of circulating cytokines [39]. To
our knowledge, this has been shown for IL-l and TNFo but
could also be the case for IL-6. Lastly, the vascular and
mesangial cell lesions commonly observed in end-stage renal
failure could similarly be involved since these cells not only
serve as cytokine targets but also produce these mediators
[40—42].
In long-term HD patients, along with elevated IL-i and
TNFc plasma predialysis levels [8], we also observed elevated
IL-6 levels. More importantly, we found that IL-6 correlates
with both IL-l and TNFa. However, it is unknown whether the
production of these cytokines is directly linked or whether this
correlation exists because IL-i or TNFa induce IL-6. Investi-
gation of the evolution of the circulating IL-6 level during the
course of the dialysis session revealed no intradialytic change.
In our previous study, we also found that TNFcw plasma level
remains unchanged during the dialysis session whereas IL-l
significantly increased [8]. However, increase of IL-6 was
observed four hours following the end of the dialysis. The
delayed onset of IL-6 production compared with IL-i as well as
the good correlation between the maximal levels of either
cytokine support the notion that dialysis related factors, includ-
ing IL-l, may contribute to amplify the secretion of IL-6. In
accord with this hypothesis, it is also noteworthy that predial-
ysis levels of IL-6 tend to decrease in the course of time in
first-dialysis patients whose plasma does not contain IL-I.
Although the exact origin of the discrepancy between the two
groups of patients remains to be elucidated, the possibility
should be considered that chronic exposure to the membrane or
the bath fluid is necessary for increasing IL-6 levels.
Direct evidence is not yet in hand to verify whether this high
increased intradialytic change in the level of IL-6 may be
responsible for the clinical manifestations seen in long-term HD
patients, in particular the rise in temperature observed during
HD [43]. However, a recent report showed that elevated IL-6
plasma level correlated with increased body temperature in
patients with severe burns [25]. Although these authors found a
mean level of IL-6 higher than in our patients (reaching 180
pg/mi), in another study [261, in patients having undergone
elective surgery, IL-6 levels were found comprised between 40
and 80 U/ml, a level which is within the range of that found in
our patients. However, particular attention must be paid to the
concomitant presence of circulating IL-I, IL-6 and TNFa in
these patients, since numerous studies support the concept that
these three factors act synergistically in a variety of biological
processes [17—19, 20, 44]. Interestingly, as in our previous study
on IL-i and TNFa [8], no major influence of the nature of the
membrane equipping the dialyzer could also be detected on
IL-6 plasma levels.
In conclusion, the data presented herein show that uremia per
se leads to induction of IL-6 as reflected by elevated plasma
levels and strongly suggest that accumulation of dialysis-in-
duced factors such as IL-l contribute to maintain raised plasma
of IL-6 during repeated dialysis sessions. Finally, our findings
demonstrate that the increased cytokine level, including not
only IL-l and TNFa but also IL-6, in the circulation in humans
is not confined to the acute inflammatory state, but also occurs
in patients with chronic inflammatory response.
Acknowledgments
The authors gratefully thank: Dr. B. Zins for her help in patient
management; F. Tresset for her technical assistance; Drs. M. Baudri-
haye and De Groote (Medgenix, Fleurus, Belgium) for the kind gift of
the anti-IL-6 mAb; Dr. F. Zavala and Dr. C. Michel-Herbelin for
valuable discussions and suggestions; and D. Broneer for revising the
manuscript. The authors are grateful to Dr. L. Aarden, Central Labo-
ratory of the Netherland Red Cross Transfusion Service for the
IL-6-sensitive B9 cell line; to Dr. M. Dy, Hôpital Necker for the
P388D1 conditioned medium; and to Ire-Medgenix for the murine
anti-human IL-6 monoclonal antibody used in this study.
Note added in proof
DESCAMPS-LATSCHA B, GOLDFARB B, NGUYEN AT, LANDAIS P,
LONDON G, HAEFFNER-CAVAILLON N, JACQUOT C, HERBELIN A,
KAZATCHKINE M: A randomized prospective study establishing the
relationship between complement activation and stimulation of phago-
cyte oxidative metabolism in hemodialyzed patients. Nephron (in press)
Reprint requests to Dr. Beatrice Descamps-Latscha, INSERM U25,
Hopital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France
References
I. OPPENHEIM JJ, KOVACS EJ, MATSUSHIMA K, DURUM SK: There is
more than one interleukin I. Immunol Today 7:45—56, 1986
2. BEUTLER B, CERAMI A: Cachectin: more than a tumor necrosis
factor. N Engl J Med 316:379—385, 1987
3. HENDERSON LW, KOCH KM, DtNARELLO CA, SHALDON 5: He-
modialysis hypotension: The interleukin hypothesis. Blood Purf
1:3—8, 1983
4. SHALDON S, KOCH KM, DINARELLO CA: Interleukin-l activation
and acute phase response during hemodialysis. Cont Nephrol
61:18—26, 1988
5. LONNEMANN G, BINGEL M, KOCH KM, SHALDON S, DINARELLO
CA: Plasma interleukin-l activity in humans undergoing hemodial-
ysis with regenerated cellulosic membranes. Lymphokine Res 6:63—
70, 1987
6. LONNEMANN G, VAN DER MEER JWM, CANNON JG, DINARELLO
CA, KOCH KM, GRANOLLERAS C, DESCHODT G, SHALDON S:
Induction of tumor necrosis factor during extracorporeal blood
purification. N Engi J Med 3 17:963—964, 1987
7. LUGER A, KOVARIK J, STUMMvOLL HK, URBANSKA A, LUGER
TA: Blood-membrane interaction in hemodialysis leads to in-
creased cytokine production. Kidney mt 32:84—88, 1988
8. HERBELIN A, NGUYEN AT, ZINGRAFF J, URENA P, DESCAMPS-
LATSCHA B: Influence of uremia and hemodialysis on circulating
interleukin-1 and tumor necrosis factor alpha. Kidney mt 37:116—
124, 1990
9. ZILBERSTEIN A, RUGGIERI R, KORN JH, REVEL M: Structure and
expression of cDNA and genes for human interferon /3-2. EMBO J
5:2529—2537, 1986
10. HAEGEMAN G, CONTENT J, VOLCKAERT G, DERYNCK R, TAVERN-
IER J, FIERS W: Structural analysis of the sequence encoding for an
inducible 26 kDa protein in human fibroblasts. Eur J Biochem
159:625—632, 1986
11. HIRANO T, YASUKAWA K, HARADA H, TAGA T, WATANABE Y,
MATSUDA T, KASHIWAMURA S, NAKAJIMA K, KOYAMA K, IwA-
MATSU A, TSUNASAWA 5, SAKIYAMA F, MATSUL H, TAKAHARA Y,
TANIGUCHI T, KIsHIMOT0 T: Complementary DNA for a novel
human interleukin (BSF-2) that induces B lymphocytes to produce
immunoglobulin. Nature 324:73—76, 1986
12. KIsHIM0T0 T: The biology of interleukin-6. Blood 74: 1—10, 1989
13. AARDEN LA, DE GROOT ER, SCHAPP OL, LANSDAP PM: Produc-
tion of hybridoma growth factor by human monocytes. Eur J
Immunol 17:1411—1416, 1987
14. OPPENHEIM JJ, MATSUSHIMA K, YOSHIMURA T, LEONARD EJ: The
activities of cytokines are pleiotropic and interdependent. Immunol
Lett 16:179—184, 1987
960 Herbelin et a!: Interleukin-6 in uremia and hemodialysis
15, LE JM, VILCEK J: Tumor necrosis factor and interleukin-1: Cyto-
kines with multiple overlapping biological activities. Lab Invest
56:234—248, 1987
16. RUDDLE NH: Tumor necrosis factor and related cytokines. Immu-
no! Today 8:129—130, 1987
17. ANDUS T, GEIGER T, HIRANO T, KIsHIM0T0 T, HEINRICH PC:
Action of recombinant interleukin-6, interleukin-l/3 and tumor
necrosis factor on the mRNA induction of acute-phase proteins.
EurJ Immunol 18:739—746, 1988
18. HURME M: Both interleukin-1 and tumor necrosis factor enhance
thymocyte proliferation. EurJ Immunol 18:1303—1306, 1988
19. LE JM, FREDRICKSON G, REI5 LF, DIAMANTSTEIN T, HIRAN0 T,
KISHIMOTO T, VILCEK J: Interleukin-2-dependent and interleukin-
2-independent pathways of regulation of thymocyte function by
interleukin-6. Proc Nat! Acad Sci USA 8:8643—8647, 1988
20. VINK A, C0uLIE PG, WAUTERS P, NORDAN RP, VAN SNIcK J: B
cell growth and differentiation activity of interleukin-HPI and
related murine plasmocytoma growth factors. Synergy with inter-
leukin-1. Eur J Immuno! 18:607—612, 1988
21. DINARELLO CA, CANNON JG, WOLFF SM, BERNHEIM HA, BEUT-
LER B, CERAMI A, FIGARI IS, PALLADINO MA, O'CONNOR JV
Tumor necrosis factor (cachectin) is an endogenous pyrogen and
induces production of interleukin-l. J Exp Med 163:1433—1450,
1986
22. SCHINDLER R, MANCILLA J, ENDRES S, GHORBANI R, CLARK SC,
DINARELLO CA: Correlations and interactions in the production of
interleukin-6 (IL-6), IL-I and tumor necrosis factor (TNF) in
human blood mononuclear cells: IL-6 suppresses IL-l and TNF.
Blood 75:40—47, 1990
23. JABLONS DM, MULE ii, MCINTOSH JK, SEGHAL PB, MAY LT,
HUANG CM, ROSENBERG SA, LOTZE AT: Interleukin-6/interferon
/3-2 as a circulating hormone: Induction by cytokine administration
in humans. J Immuno! 142:1542—1547, 1989
24. HntNo T, KIsHIMOT0 T: Peptides, growth factors and their
receptors, in Handbook of Experimental Pharmacology, edited by
SPORN MB, ROBERTS AB, Berlin, Springer-Verlag, 1989
25. NIJSTEN MWN, DE GROOT ER, TEN Duls HJ, KLASEN Hi, HACK
CE, AARDEN LA: Serum levels of interleukin-6 and acute phase
responses. Lance! 2:921, 1987
26. SHENKIN A, FRASER WD, SERIES J, WINSTANLEY FP, MCCART-
NEY AC, BURNS hG, VAN DAMME J: The serum interleukin-6
response to elective surgery. Lymphokine Res 8:123—127, 1989
27. MOSMANN T: Rapid colonmetric assay for cellular growth and
survival: Application to proliferation and cytotoxicity assays. J
Immuno! Meth 65:55—63, 1983
28. BERGSTROM J, WEHLE B: No change in corrected /32-mieroglobulin
concentration after cuprophan hemodialysis. Lancet 1:628-629,
1987
29. KUPPER TS, MIN K, SEHGAL P, MIZUTANI H, BIRCHALL N, RAY
A, MAY L: Production of IL-6 by keratinocytes. Ann NYAcad Sci
557:454—464, 1989
30. BEAURAIN 0, NARET C, MARCON L, GRATEAU G, DRUEKE T,
URENA P, NELSON DL, BACH iF, CHATENOUD L: In vivo T cell
activation in chronic uremic hemodialyzed and non-hemodialyzed
patients. Kidney mt 36:636—644, 1989
31. LE JM, FREDRICKSON G, POLLACK M, VILCEK J: Activation of
thymocytes and T cells by interleukin-6. Ann NY Acad Sci 557:
444—452, 1989
32. HoRn Y, MURAGUCHI A, SUEMATSU S, MATSUDA T, YOSHIZAKI
K, HIRANO T, KISHIM0T0 T: Regulation of BSF-2/IL-6 production
by human mononuclear cells. Macrophage dependent synthesis of
BSF-2/IL-6 by T cells. J Immunol 141:1529—1535, 1988
33. FONG YM, MOLDAWER LL, MARANO MM, WE! H, TATTER SB,
CLARICK RH, SANTHANAM U, SHERRIS D, MAY LT, SEGHAL PB,
LOWRY SF: Endotoxemia elicits increased circulating 132-interfer-
on/interleukin-6 in man. J Immuno! 142:2321—2324, 1989
34. MICHIE HR, MANOGUE KR, SPRIGGS DR, REUAUG A, D'DWYER
S, DINARELLO CA, CERAMI A, WOLFF SM, WILMORE DW: Detec-
tion of circulating tumor necrosis factor after endotoxin adminis-
tration. N Eng! J Med 318: 1481—1486, 1988
35. NISBETH U, HALLGREN R, ERIKSSON 0, DANIELSON BG: Endo-
toxemia in chronic renal failure. Nephron 45:93—97, 1987
36. KIMBALL ES, PICKERAL SF, OPPENHEIM JJ, RosSio JL: Interleu-
kin-I activity in normal human urine. J Immuno! 133:256—260, 1984
37. TOWNSEND Y, CRANSTON WI: Site of clearance of leukocyte
pyrogen in rabbit. Clin Sd 56:265—268, 1979
38. SCHINDLER R, ENDRES S, GHORBANI R, DINARELLO CA: Interleu-
kin-6 production by human mononuclear cells and comparison to
IL-l alpha, beta and TNF. (abstract) LymphokineRes 8:3llA, 1988
39. HESSION C, DECKER JM, SHERBLOM AP, KUMAR 5, YUE CC,
MATTALIANO Ri, TIZARD R, KAWASHIMA E, SCHMEISSNER U,
HELETKI S, CHOW EP, BURNE CA, SHAW A, MUCHMORE AV:
Uromodulin (Tamm-Horsfall glycoprotein): A renal ligand for lym-
phokines. Science 237:1479-1485, 1987
40. LOPPNOW H, LIBBY P: Proliferation or interleukin-l activated
human vascular smooth muscle cells secrete copious interleukin-6.
J C!in Invest 85:731—738, 1990
41. BAUD L, OUDINET iP, BENS M, NOE L, ETIENNE J, ARDAILLOU
R: Production of tumor necrosis factor by rat mesangial cells in
response to bacterial lipopolysaccharide. Kidney In! 35:1111—1118,
1989
42. BENFIELD MR, WALKER P, NELSON P, MICHAEL AF, KIM Y: IL-6
production by human mesangial cells in culture. (abstract) Kidney
In! 37:408, 1990
43. BINGEL M, LONNEMANN G, KOCH KM. DINARELLO CA, SHAL-
DON S: Plasma interleukin-l activity during hemodialysis: the
influence of dialysis membranes. Nephron 5:273—276, 1988
44. MOLDAWER LL, BUSHMAN ED, BARBER A, MARANO MA, KEOGH
C, FONG Y, HELFGOTT DC, MAY LT, SEHGAL P, LOWRY SF:
Interleukin- 1 and interleukin-6 synergize to increase plasma amy-
bid P and C3 concentrations in the mouse. AnnNY Acad Sci
557:528—531, 1989
